Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neal Rosen

Showing results (21-30 of 207) with videos related to

Pageof 21
Sort By:
Bioorganic & Medicinal Chemistry|September 6, 2002
Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinaseGabriela Chiosis, Brian Lucas, Alexander Shtil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?Mario E Lacouture, Kathryn O'Reilly, Neal Rosen, et al.
Nature Reviews. Clinical Oncology|January 26, 2024
BRAF - a tumour-agnostic drug target with lineage-specific dependenciesAphrothiti J Hanrahan, Ziyu Chen, Neal Rosen, et al.
Oncogene|February 19, 2002
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2Andrea D Basso, David B Solit, Pamela N Munster, et al.
Cancer Research|May 31, 2002
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathwayPamela N Münster, Douglas C Marchion, Andrea D Basso, et al.
Science (New York, N.Y.)|February 4, 2016
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanismPiro Lito, Martha Solomon, Lian-Sheng Li, et al.
Molecular Cancer Therapeutics|February 18, 2003
17AAG: low target binding affinity and potent cell activity--finding an explanationGabriela Chiosis, Henri Huezo, Neal Rosen, et al.
Current Cancer Drug Targets|October 8, 2003
Development of purine-scaffold small molecule inhibitors of Hsp90Gabriela Chiosis, Brian Lucas, Henri Huezo, et al.
The Journal of Biological Chemistry|May 23, 2012
Inhibition of mycobacterial infection by the tumor suppressor PTENGuochang Huang, Gil Redelman-Sidi, Neal Rosen, et al.
Nature|February 25, 2010
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFPoulikos I Poulikakos, Chao Zhang, Gideon Bollag, et al.
Pageof 21

Showing results (21-30 of 207) with videos related to

Sort By:
Pageof 21
Bioorganic & Medicinal Chemistry|September 6, 2002
Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinaseGabriela Chiosis, Brian Lucas, Alexander Shtil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?Mario E Lacouture, Kathryn O'Reilly, Neal Rosen, et al.
Nature Reviews. Clinical Oncology|January 26, 2024
BRAF - a tumour-agnostic drug target with lineage-specific dependenciesAphrothiti J Hanrahan, Ziyu Chen, Neal Rosen, et al.
Oncogene|February 19, 2002
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2Andrea D Basso, David B Solit, Pamela N Munster, et al.
Cancer Research|May 31, 2002
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathwayPamela N Münster, Douglas C Marchion, Andrea D Basso, et al.
Science (New York, N.Y.)|February 4, 2016
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanismPiro Lito, Martha Solomon, Lian-Sheng Li, et al.
Molecular Cancer Therapeutics|February 18, 2003
17AAG: low target binding affinity and potent cell activity--finding an explanationGabriela Chiosis, Henri Huezo, Neal Rosen, et al.
Current Cancer Drug Targets|October 8, 2003
Development of purine-scaffold small molecule inhibitors of Hsp90Gabriela Chiosis, Brian Lucas, Henri Huezo, et al.
The Journal of Biological Chemistry|May 23, 2012
Inhibition of mycobacterial infection by the tumor suppressor PTENGuochang Huang, Gil Redelman-Sidi, Neal Rosen, et al.
Nature|February 25, 2010
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFPoulikos I Poulikakos, Chao Zhang, Gideon Bollag, et al.
Pageof 21